PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Aerivio Spiromax (Fluticasone/Salmeterol) DPI - Asthma

PAD Profile : Aerivio Spiromax (Fluticasone/Salmeterol) DPI - Asthma

Keywords :
ICS LABAs, ICS/LABAs, inhaled corticosteroids, long-acting beta agonists, respiratory, asthmatics

Traffic Light Status

Status 1 of 1.

Status :
Black
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Fostair® (beclometasone / formoterol) metered dose inhaler is the locally preferred ICS/LABA.
Fostair Nexthaler ® breath-actuated inhaler is the preferred dry powder ICS/LABA device.

If patient cannot tolerate formoterol, a salmeterol / fluticasone combination may be indicated.
Combisal® (fluticasone / salmeterol) metered dose inhaler is the locally preferred device.
Seretide Accuhaler® is the locally preferred futicasone/salmeterol breath-actuated device (for use when patient cannot tolerate formoterol (Fostair Nexthaler)

NOTE: 
- The Aerivio Spiroma®x device is not recommended for use in any health setting across Surrey and NW Sussex health economy.
- Aerivio Spiromax® is ONLY available in a high dose device
- Aerivio Spiromax® is not licensed for maintenance and reliever therapy (MART)

Prescribe inhaler devices by BRAND to ensure consistency and avoid confusion.

See Asthma Guidelines below.

Associated BNF Codes

03. Respiratory System
03.02.00. Corticosteroids (respiratory)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More